ATE209644T1 - 1,2,3,4-tetrahydroquinoxalindion derivate und ihre verwendung als glutamat rezeptor antagonisten - Google Patents
1,2,3,4-tetrahydroquinoxalindion derivate und ihre verwendung als glutamat rezeptor antagonistenInfo
- Publication number
- ATE209644T1 ATE209644T1 AT95932217T AT95932217T ATE209644T1 AT E209644 T1 ATE209644 T1 AT E209644T1 AT 95932217 T AT95932217 T AT 95932217T AT 95932217 T AT95932217 T AT 95932217T AT E209644 T1 ATE209644 T1 AT E209644T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- substituted
- carboxyl
- mono
- salt
- Prior art date
Links
- ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical class C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940098747 AMPA receptor antagonist Drugs 0.000 abstract 1
- 239000000775 AMPA receptor antagonist Substances 0.000 abstract 1
- 229940122165 Glycine receptor antagonist Drugs 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 239000002430 glycine receptor antagonist Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 abstract 1
- 229950006874 kainic acid Drugs 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 phenyloxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23190894 | 1994-09-27 | ||
| JP5948295 | 1995-03-17 | ||
| PCT/JP1995/001922 WO1996010023A1 (en) | 1994-09-27 | 1995-09-25 | 1,2,3,4-tetrahydroquinoxalindione derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE209644T1 true ATE209644T1 (de) | 2001-12-15 |
Family
ID=26400527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95932217T ATE209644T1 (de) | 1994-09-27 | 1995-09-25 | 1,2,3,4-tetrahydroquinoxalindion derivate und ihre verwendung als glutamat rezeptor antagonisten |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6096743A (de) |
| EP (1) | EP0784054B1 (de) |
| KR (1) | KR100392151B1 (de) |
| CN (1) | CN1067387C (de) |
| AT (1) | ATE209644T1 (de) |
| CA (1) | CA2199468C (de) |
| DE (1) | DE69524246T2 (de) |
| DK (1) | DK0784054T3 (de) |
| ES (1) | ES2168383T3 (de) |
| HU (1) | HU223945B1 (de) |
| MX (1) | MX9702244A (de) |
| PL (1) | PL181532B1 (de) |
| PT (1) | PT784054E (de) |
| RU (1) | RU2149873C1 (de) |
| UA (1) | UA44283C2 (de) |
| WO (1) | WO1996010023A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057304A (en) * | 1992-10-26 | 2000-05-02 | Schering Aktiengesellschaft | Quinoxaline-phosphonic acid derivatives |
| DE19519979A1 (de) * | 1995-05-24 | 1996-11-28 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| TW448171B (en) * | 1996-06-06 | 2001-08-01 | Yamanouchi Pharma Co Ltd | Imidazole-substituted quinoxalinedione derivatives |
| AU6310498A (en) | 1997-03-14 | 1998-10-12 | Meiji Seika Kaisha Ltd. | Physiologically active substance pf1191 and process for producing the same |
| DE19728326A1 (de) * | 1997-06-27 | 1999-01-07 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| IL139783A0 (en) | 1998-06-01 | 2002-02-10 | Shionogi & Co | Cyanoiminoquinoxaline derivates |
| WO2000047567A1 (en) | 1999-02-15 | 2000-08-17 | Eisai Co., Ltd. | Heterodiazinone derivatives |
| US6599942B1 (en) | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
| US6790978B2 (en) | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
| US6709667B1 (en) | 1999-08-23 | 2004-03-23 | Conceptus, Inc. | Deployment actuation system for intrafallopian contraception |
| EP1736468A3 (de) * | 2000-01-24 | 2007-01-03 | NeuroSearch A/S | Isatinderivate mit neurotropischer Aktivität geeignet zur Behandlung von NGF-bedingten Krankheiten |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| US7029872B2 (en) * | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| JP2005506292A (ja) * | 2001-03-08 | 2005-03-03 | エモリー ユニバーシティ | ｐＨに依存するＮＭＤＡレセプターアンタゴニスト |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| AU2003220825A1 (en) * | 2002-03-29 | 2003-10-13 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for glioblastoma |
| US20050130978A1 (en) * | 2002-04-17 | 2005-06-16 | Masamichi Yuda | Novel crystal of quinoxalinedione derivative anhydride |
| CA2490688A1 (en) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | Therapeutic agent for brain hemorrhage |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| GB0405034D0 (en) * | 2004-03-05 | 2004-04-07 | Novartis Ag | Organic compounds |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| JP5180816B2 (ja) * | 2005-04-04 | 2013-04-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患および認知症のためのジヒドロピリジン化合物 |
| WO2007020521A1 (en) * | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Pyridoyrazinones as pde-5 inhibitors |
| EP2151436B1 (de) * | 2007-05-29 | 2013-04-24 | Santen Pharmaceutical Co., Ltd | Neuartiges 1,2,3,4-tetrahydrochinoxalin-derivat mit einer als substituent eingefügten phenylgruppe, die eine schwefelsäureesterstruktur oder eine schwefelsäureamidstruktur aufweist, sowie mit glucocorticoidrezeptor-bindungswirkung |
| KR20100045983A (ko) | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 ｎｍｄａ 수용체 길항물질 |
| WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| EP2338492A1 (de) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Verfahren und Zusammensetzung zur Behandlung von Alzheimer |
| WO2020124090A1 (en) | 2018-12-14 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
| JPWO2023042888A1 (de) | 2021-09-15 | 2023-03-23 | ||
| JPWO2023042887A1 (de) | 2021-09-15 | 2023-03-23 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221425B (en) * | 1990-11-06 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds |
| PT101004B (pt) * | 1991-10-26 | 1999-10-29 | Schering Ag | Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem |
| IL109397A0 (en) * | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPH07165756A (ja) * | 1993-12-14 | 1995-06-27 | Yamanouchi Pharmaceut Co Ltd | ヒドロキシキノキサリンジオン誘導体 |
| US5654303A (en) * | 1995-06-07 | 1997-08-05 | Warner-Lambert Company | Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
-
1995
- 1995-09-25 PT PT95932217T patent/PT784054E/pt unknown
- 1995-09-25 EP EP95932217A patent/EP0784054B1/de not_active Expired - Lifetime
- 1995-09-25 CN CN95195237A patent/CN1067387C/zh not_active Expired - Fee Related
- 1995-09-25 UA UA97031348A patent/UA44283C2/uk unknown
- 1995-09-25 CA CA002199468A patent/CA2199468C/en not_active Expired - Fee Related
- 1995-09-25 AT AT95932217T patent/ATE209644T1/de not_active IP Right Cessation
- 1995-09-25 MX MX9702244A patent/MX9702244A/es not_active IP Right Cessation
- 1995-09-25 DE DE69524246T patent/DE69524246T2/de not_active Expired - Fee Related
- 1995-09-25 HU HU9702043A patent/HU223945B1/hu not_active IP Right Cessation
- 1995-09-25 KR KR1019970701879A patent/KR100392151B1/ko not_active Expired - Fee Related
- 1995-09-25 US US08/809,087 patent/US6096743A/en not_active Expired - Fee Related
- 1995-09-25 ES ES95932217T patent/ES2168383T3/es not_active Expired - Lifetime
- 1995-09-25 RU RU97104870/04A patent/RU2149873C1/ru not_active IP Right Cessation
- 1995-09-25 DK DK95932217T patent/DK0784054T3/da active
- 1995-09-25 WO PCT/JP1995/001922 patent/WO1996010023A1/ja not_active Ceased
- 1995-09-25 PL PL95320059A patent/PL181532B1/pl not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996010023A1 (en) | 1996-04-04 |
| KR100392151B1 (ko) | 2003-11-20 |
| EP0784054A1 (de) | 1997-07-16 |
| PL320059A1 (en) | 1997-09-01 |
| RU2149873C1 (ru) | 2000-05-27 |
| MX9702244A (es) | 1997-06-28 |
| EP0784054B1 (de) | 2001-11-28 |
| AU684392B2 (en) | 1997-12-11 |
| CA2199468C (en) | 2006-06-06 |
| AU3533795A (en) | 1996-04-19 |
| DK0784054T3 (da) | 2002-03-25 |
| PL181532B1 (pl) | 2001-08-31 |
| DE69524246T2 (de) | 2002-06-27 |
| ES2168383T3 (es) | 2002-06-16 |
| HUT77442A (hu) | 1998-04-28 |
| CN1067387C (zh) | 2001-06-20 |
| US6096743A (en) | 2000-08-01 |
| UA44283C2 (uk) | 2002-02-15 |
| PT784054E (pt) | 2002-05-31 |
| KR970706274A (ko) | 1997-11-03 |
| EP0784054A4 (de) | 1998-01-07 |
| DE69524246D1 (de) | 2002-01-10 |
| HU223945B1 (hu) | 2005-03-29 |
| CN1168670A (zh) | 1997-12-24 |
| CA2199468A1 (en) | 1996-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69524246D1 (de) | 1,2,3,4-Tetrahydroquinoxalindion Derivate und ihre Verwendung als Glutamat Rezeptor Antagonisten | |
| AU651986B2 (en) | Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same | |
| ATE206412T1 (de) | Heterocyclische verbindungen als bradykinin antagonisten | |
| CA2311742A1 (en) | 6-amino-9-benzyl-8-hydroxypurine derivatives | |
| EP0976748A4 (de) | Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben | |
| ATE448226T1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| ATE232520T1 (de) | Imidazolidin-4-on derivate verwendbar als antikrebsmittel | |
| IL101785A0 (en) | Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| RU97104870A (ru) | 1,2,3,4-тетрагидрохиноксалиндионовое производное | |
| DK0609289T3 (da) | Imidazolderivater og farmaceutiske præparater med indhold deraf | |
| EP1340748A4 (de) | Chinazolinderivate und -arzneimittel | |
| DE60016384D1 (de) | Chondrogonese promotoren und indolin-2-on derivate | |
| ATE170851T1 (de) | Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten | |
| DE69911557D1 (de) | Imidazoline Derivate,ihre Herstellung und pharmazeutische Zusammensetzungen die sie enthalten | |
| NO20053302L (no) | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |